Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSI NASDAQ:BSTC NASDAQ:BTAI NASDAQ:GTHX NASDAQ:KURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSIBioDelivery Sciences International$5.59$5.58$2.50▼$5.62$577.05M0.563.34 million shs2.09 million shsBSTCBioSpecifics Technologies$88.53$88.47$42.00▼$89.15$650.25M0.2461,105 shsN/ABTAIBioXcel Therapeutics$1.97-1.5%$1.65$1.17▼$21.92$12.11M0.041.22 million shs140,279 shsGTHXG1 Therapeutics$7.15$7.13$1.08▼$7.19$373.81M1.661.70 million shsN/AKURAKura Oncology$6.28-1.3%$6.07$5.41▼$23.48$550.61M0.41.27 million shs1.20 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSIBioDelivery Sciences International0.00%0.00%0.00%0.00%0.00%BSTCBioSpecifics Technologies0.00%0.00%0.00%0.00%0.00%BTAIBioXcel Therapeutics0.00%+2.04%+0.50%+10.50%-88.64%GTHXG1 Therapeutics0.00%0.00%0.00%0.00%+156.27%KURAKura Oncology+3.25%+7.61%-6.61%+10.23%-68.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDSIBioDelivery Sciences InternationalN/AN/AN/AN/AN/AN/AN/AN/ABSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ABTAIBioXcel Therapeutics4.2064 of 5 stars3.32.00.04.53.31.70.6GTHXG1 TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKURAKura Oncology4.4149 of 5 stars4.42.00.04.72.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSIBioDelivery Sciences International 0.00N/AN/AN/ABSTCBioSpecifics Technologies 0.00N/AN/AN/ABTAIBioXcel Therapeutics 2.67Moderate Buy$42.602,062.44% UpsideGTHXG1 Therapeutics 2.00HoldN/AN/AKURAKura Oncology 2.86Moderate Buy$24.50290.13% UpsideCurrent Analyst Ratings BreakdownLatest KURA, BTAI, BDSI, GTHX, and BSTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025KURAKura OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight6/20/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$36.006/4/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.005/19/2025KURAKura OncologyMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.005/2/2025KURAKura OncologyBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $11.004/29/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.00 ➝ $28.004/28/2025KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSIBioDelivery Sciences International$166.70M3.46$0.36 per share15.42$1.90 per share2.94BSTCBioSpecifics Technologies$38.19M17.03$3.38 per share26.18$18.42 per share4.81BTAIBioXcel Therapeutics$2.27M5.26N/AN/A($30.01) per share-0.07GTHXG1 Therapeutics$58.20M6.42N/AN/A$0.68 per share10.51KURAKura Oncology$53.88M10.09N/AN/A$5.32 per share1.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSIBioDelivery Sciences International$84.86M$0.836.748.47N/A50.90%21.25%10.56%N/ABSTCBioSpecifics Technologies$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/ABTAIBioXcel Therapeutics-$59.60M-$13.55N/AN/AN/A-2,163.18%N/A-83.80%8/5/2025 (Estimated)GTHXG1 Therapeutics-$47.97M-$0.62N/AN/AN/A-76.93%-136.98%-39.33%N/AKURAKura Oncology-$173.98M-$2.10N/AN/AN/AN/A-43.62%-29.13%8/6/2025 (Estimated)Latest KURA, BTAI, BDSI, GTHX, and BSTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025BTAIBioXcel Therapeutics-$2.30N/AN/AN/A$0.21 millionN/A5/12/2025Q1 2025BTAIBioXcel Therapeutics-$2.72-$1.50+$1.22-$1.50$0.35 million$0.17 million5/1/2025Q1 2025KURAKura Oncology-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDSIBioDelivery Sciences InternationalN/AN/AN/AN/AN/ABSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSIBioDelivery Sciences International0.292.452.17BSTCBioSpecifics TechnologiesN/A66.2466.24BTAIBioXcel TherapeuticsN/A1.481.45GTHXG1 Therapeutics1.342.482.12KURAKura Oncology0.028.078.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSIBioDelivery Sciences International64.40%BSTCBioSpecifics Technologies60.34%BTAIBioXcel Therapeutics30.68%GTHXG1 Therapeutics24.21%KURAKura OncologyN/AInsider OwnershipCompanyInsider OwnershipBDSIBioDelivery Sciences International9.98%BSTCBioSpecifics Technologies15.70%BTAIBioXcel Therapeutics21.20%GTHXG1 Therapeutics6.11%KURAKura Oncology6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSIBioDelivery Sciences International200103.23 million92.93 millionOptionableBSTCBioSpecifics Technologies77.35 millionN/ANot OptionableBTAIBioXcel Therapeutics906.06 million4.77 millionOptionableGTHXG1 Therapeutics17052.28 million49.09 millionOptionableKURAKura Oncology13086.57 million81.03 millionOptionableKURA, BTAI, BDSI, GTHX, and BSTC HeadlinesRecent News About These CompaniesKura Oncology (NASDAQ:KURA) Stock Crosses Below 200-Day Moving Average - Should You Sell?July 10 at 7:19 AM | marketbeat.comKura Oncology Grants Stock Options to New Employees Under 2023 Inducement Option Plan - NasdaqJuly 5, 2025 | nasdaq.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comKura Oncology and Kyowa Kirin enter agreement to co-promote leukemia drug in US - Investing.comJuly 2, 2025 | investing.comKura Oncology's (KURA) Overweight Rating Reaffirmed at Cantor FitzgeraldJune 26, 2025 | marketbeat.comKura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by AnalystsJune 23, 2025 | marketbeat.comKura Oncology (NASDAQ:KURA) Receives "Outperform" Rating from WedbushJune 20, 2025 | marketbeat.comKura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlookJune 15, 2025 | investing.comIs the Options Market Predicting a Spike in Kura Oncology Stock?June 12, 2025 | zacks.comKura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association CongressJune 12, 2025 | globenewswire.comLightning Round: 'Wait and see situation' with Papa John's, says Jim CramerJune 12, 2025 | msn.comKura Oncology Grants Stock Options To New Hires Under Inducement PlanJune 7, 2025 | nasdaq.comKURA Stock Rises More Than 15% This Past Week: Here's WhyJune 6, 2025 | zacks.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comFDA Grants Priority Review to Ziftomenib Application in NPM1-Mutated Acute Myeloid LeukemiaJune 5, 2025 | precisionmedicineonline.comPFDA Grants Priority Review to NDA of Ziftomenib in NPM1-Mutant AMLJune 4, 2025 | targetedonc.comTASCO25: Kura’s Phase II ziftomenib results trigger NDA acceptance from FDAJune 3, 2025 | finance.yahoo.comASCO: Kura, Kyowa reveal 23% remission rate behind oral leukemia drug's phase 2 winJune 2, 2025 | fiercebiotech.comFKura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual MeetingJune 2, 2025 | globenewswire.comFDA Grants Priority Review for Kura Oncology, Inc. (KURA) and Kyowa Kirin’s ZiftomenibJune 2, 2025 | insidermonkey.comKura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AMLJune 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKURA, BTAI, BDSI, GTHX, and BSTC Company DescriptionsBioDelivery Sciences International NASDAQ:BDSIBioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.BioSpecifics Technologies NASDAQ:BSTCBioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.BioXcel Therapeutics NASDAQ:BTAI$1.97 -0.03 (-1.50%) Closing price 04:00 PM EasternExtended Trading$2.00 +0.03 (+1.47%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.G1 Therapeutics NASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Kura Oncology NASDAQ:KURA$6.28 -0.08 (-1.26%) Closing price 04:00 PM EasternExtended Trading$6.28 +0.00 (+0.08%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
